IgA nephropathy: An update

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 2, 2004, Pages 171-179

  Julian, Bruce A ^a   Novak, Jan ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Cytokine; Glycosylation; IgA nephropathy; Mesangial cell

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GALACTOSE; GLUCOCORTICOID; GLYCAN DERIVATIVE; IMMUNOGLOBULIN A1; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; MATRIX PROTEIN; PLACEBO; PREDNISONE; SPIRONOLACTONE;

CELL PROLIFERATION; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; IMMUNE COMPLEX DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; MESANGIUM CELL; META ANALYSIS; MULTICENTER STUDY; NEPHRECTOMY; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A;

EID: 1642347824     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200403000-00005     Document Type: Review

References (85)

1. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12:340-347.
2. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36:227-237.
3. Geddes CC, Rauta V, Gronhagen-Riska C, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18:1541-1548. This retrospective analysis of 711 adult patients with IgA nephropathy from Glasgow, UK; Helsinki, Finland; Sydney, Australia; and Toronto, Canada found a geographical variability in renal survival and the slope of creatinine clearance. When age, creatinine clearance, proteinuria, and mean arterial blood pressure at clinical presentation were taken into account, the variability related mostly to leadtime bias and the inclusion of milder cases at centers with apparently good outcomes.
4. Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286-2294. This study in Japan of 446 living-and 64 deceased-donor renal allografts showed that latent IgA nephropathy was common, and the frequency did not differ by the donor source.
5. Maeda A, Gohda T, Funabiki K, et al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal 2003; 17:73-76. In an effort to identify IgA nephropathy patients without a renal biopsy, the authors found that 82% of patients with IgA nephropathy versus 35% of patients with other primary renal diseases had at least three of the following laboratory findings: serum IgA/C3 ratio greater than 3.01, more than five red blood cells per high-power field on urinalysis, persistent proteinuria greater than 0.3 g/day, and a serum IgA level greater than 315 mg/dl.
6. Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis 1988; 12:348-352.
7. Allen AC, Bailey EM, Brenchley PEC, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observation in three patients. Kidney Int 2001; 60:969-973.
8. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077-1085.
9. Fervenza FC. Henoch-Schönlein purpura nephritis. Int J Dermatol 2003; 42:170-177. This review is an excellent summary of the clinical features, renal pathology, pathogenesis, and treatment of HSP nephritis.
10. Field MC, Dwek RA, Edge CJ, et al. O-linked oligosaccharides from human serum immunoglobulin A1. Biochem Soc Trans 1989; 17:1034-1035.
11. Mattu TS, Pleass RJ, Willis AC, et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem 1998; 273:2260-2272.
12. Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997; 52:509-516.
13. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104:73-81.
14. Iwasaki H, Zhang Y, Tachibana K, et al. Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-acetylgalactosaminyltransferase 2. J Biol Chem 2003; 278:5613-5621. This elegant study shows the specificities of several N-acetylgalactosamine transferases for different acceptors. One enzyme was specific for the IgA1 hinge-region peptide.
15. Ju T, Brewer K, D'Souza A, et al. Cloning and expression of human core 1 β1,3-galactosyltransferase. J Biol Chem 2002; 277:178-186.
16. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase. Proc Natl Acad Sci U S A 2002; 99:16613-16618. See notes for Ref [17*].
17. Kudo T, Iwai T, Kubota T, et al. Molecular cloning and characterization of a novel UDP-Gal:GalNAcα peptide β1,3-galactosyltransferase (C1Gal-T2), an enzyme synthesizing a core 1 structure of O-glycan. J Biol Chem 2002; 277:47724-47731. These two papers (Refs [16*,17*]) show an unusual regulation of β1,3-galactosyltransferase via a chaperone called Cosmc.
18. Mestecky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993; 104:172-182.
19. Allen AC, Harper SJ, Feehally J. Galactosylation of N-and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995; 100:470-474.
20. Tomino Y, Ohmuro H, Takahashi Y, et al. Binding capacity of serum IgA to jacalin in patients with IgA nephropathy using jacalin-coated microplates. Nephron 1995; 70:329-333.
21. Hiki Y, Horii A, Iwase H, et al. O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role. Contrib Nephrol 1995; 111:73-84.
22. Allen AC, Willis FR, Beattie TJ, et al. Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 1998; 13:930-934.
23. Allen AC, Topham PS, Harper SJ, et al. Leucocyte β1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997; 12:701-706.
24. Smith AC, Feehally J. New insights into the pathogenesis of IgA nephropathy. Pathogenesis of IgA nephropathy. Springer Semin Immunopathol 2003; 24:477-493. This review is an excellent up-to-date summary of the understanding of the pathogenesis of IgA nephropathy.
25. Novak J, Julian BA, Tomana M, et al. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 2001; 21:310-327.
26. Mestecky J, Novak J, Julian BA, et al. Pathogenic potential of galactose-deficient IgA1 in IgA nephropathy. Nephrology 2002; 7:S92-S99.
27. Iwase H, Katsumata T, Itoh A, et al. Detection of enriched Thomsen-Friedenrich antigen on IgA1 from IgA nephropathy patients. J Nephrol 2002; 15:703-708.
28. Hiki Y, Iwase H, Kokubo T, et al. Association of asialo-galactosyl β1-3N-acetylgalactosamine on the hinge with a conformational instability of jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy. J Am Soc Nephrol 1996; 7:955-960.
29. van der Boog PJ, De Fijter JW, Van Kooten C, et al. Complexes of IgA with Fcα RI/CD89 are not specific for primary IgA nephropathy. Kidney Int 2003; 63:514-521. This paper demonstrates that IgA-CD89 complexes are present in the serum of patients with IgA nephropathy and in that of healthy individuals.
30. Linossier MT, Palle S, Berthoux F. Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basement membrane thickness: normal versus thin. Am J Kidney Dis 2003; 41:558-564. Among patients with IgA nephropathy, those with thin glomerular basement membranes have a better clinical prognosis than patients with glomerular basement membranes of normal thickness. This study showed that patients in the latter group exhibited abnormal IgA1 glycosylation.
31. van der Helm-van Mil AHM, Smith AC, Pouria S, et al. Immunoglobulin A multiple myeloma presenting with Henoch-Schönlein purpura associated with reduced sialylation of IgA1. Br J Haematol 2003; 122:915-917. This case report describes two patients with HSP and IgA multiple myeloma with abnormal glycosylation of IgA.
32. Silva FG, Chander P, Pirani CL, et al. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 1982; 33:241-246.
33. van den Wall Bake AWL, Bruijn JA, Accavitti MA, et al. Shared idiotypes in mesangial deposits in IgA nephropathy are not disease-specific. Kidney Int 1993; 44:65-74.
34. Leung JC, Tsang AW, Chan LY, et al. Size-dependent binding of IgA to HepG2, U937, and human mesangial cells. J Lab Clin Med 2002; 140:398-406. This elaborate study compared the affinities of various molecular forms of IgA with different cells.
35. Itoh A, Iwase H, Takatani T, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant 2003; 18:1108-1114. This study found that tonsillar B cells of IgA nephropathy patients produce abnormally glycosylated IgA1.
36. Julian BA, Tomana M, Novak J, et al. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol 1999; 29:53-72.
37. Monteiro RC, Van De Winkel JG. IgA Fc Receptors. Annu Rev Immunol 2003; 21:177-204. This paper is an excellent review of the current knowledge about IgA receptors.
38. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194:417-425.
39. Haddad E, Moura IC, Arcos-Fajardo M, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14:327-337. This study investigated the expression of an IgA1 receptor, CD71, in renal biopsy tissue of patients with IgA nephropathy or HSP nephritis.
40. McDonald KJ, Cameron AJM, Allen JM, et al. Expression of Fcα/μ receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002; 290:438-442.
41. Leung JC, Tang SC, Chan LY, et al. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 2003; 18:36-45. This study demonstrated the upregulation of macrophage migration inhibitory factor by polymeric IgA from IgA nephropathy patients, and indicated a possible involvement of a new IgA receptor.
42. Chen A, Chen WP, Sheu LF, et al. Pathogenesis of IgA nephropathy: in vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion. J Pathol 1994; 173:119-126.
43. Schöcklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int 1999; 56:1199-1207.
44. Duque N, Gomez-Guerrero C, Egido J. Interaction of IgA with Fcα receptors of human mesangial cells activates transcription factor nuclear factor-κB and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 1997; 159:3474-3482.
45. Fujii K, Muller KD, Clarkson AR, et al. The effect of IgA immune complexes on the proliferation of cultured human mesangial cells. Am J Kidney Dis 1990; 16:207-210.
46. Haas CS, Schöcklmann HO, Lang S, et al. Regulatory mechanism in glomerular mesangial cell proliferation. J Nephrol 1999; 12:405-415.
47. Harada K, Akai Y, Kurumatani N, et al. Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study. Nephron 2002; 92:824-826.
48. Arrizabalaga P, Sole M, Abellana R, et al. Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy. Am J Nephrol 2003; 23:121-128. This study found that tubular and interstitial expression of intercellular adhesion molecule type 1 is a marker of tubulointerstitial damage in IgA nephropathy.
49. Lim CS, Yoon HJ, Kim YS, et al. Clinicopathological correlation of intrarenal cytokines and chemokines in IgA nephropathy. Nephrology 2003; 8:21-27. This study showed that levels of gene transcripts of various cytokines correlated with the severity of glomerular, tubulointerstitial, and vascular damage in IgA nephropathy.
50. Gagliardini E, Benigni A, Tomasoni S, et al. Targeted downregulation of extracellular nephrin in human IgA nephropathy. Am J Nephrol 2003; 23:277-286. This study shows that the ultrastructure of the filtration slit diaphragm is altered in IgA nephropathy patients as a result of the targeted downregulation of extracellular nephrin.
51. Yano N, Endoh M, Fadden K, et al. Comprehensive gene expression profile of the adult human renal cortex: analysis by cDNA array hybridization. Kidney Int 2000; 57:1452-1459.
52. Sakai H, Yano N, Fadden-Paiva KJ, et al. IgA nephropathy and mesangial cell proliferation: shared global gene expression profiles. Nephrology 2002; 7:S106-S113.
53. Yano N, Fadden-Paiva KJ, Endoh M, et al. Profiling the IgA nephropathy renal transcriptome: analysis by complementary DNA array hybridization. Nephrology 2002; 7:S140-S144.
54. Waga I, Yamamoto J, Sasai H, et al. Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. Kidney Int 2003; 64:1253-1264. This paper described a novel approach to large-scale differential gene expression in IgA nephropathy renal tissue. Interesting techniques, including bioinformatics, were used.
55. Ashizawa M, Miyazaki M, Abe K, et al. Detection of nuclear factor-κB in IgA nephropathy using Southwestern histochemistry. Am J Kidney Dis 2003; 42:76-86. This study clearly demonstrates a role for NF-κB in the progression of IgA nephropathy.
56. Bussolati B, Peri G, Salvidio G, et al. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 2003; 170:1466-1472. This paper demonstrates a role for a long petraxin in mesangial cell proliferation in IgA nephropathy.
57. Del Prete D, Gambaro G, Lupo A, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulo-nephritis. Kidney Int 2003; 64:149-159. This study shows that the renin-angiotensin system is activated in IgA nephropathy and plays an important role in the inflammation in the glomeruli and interstitium after the deposition of IgA1. These findings strengthen the rationale for early treatment with ACE inhibitors and angiotensin II type 1 receptor blockers, even in the absence of hypertension or severe proteinuria.
58. Tuglular S, Berthoux P, Berthoux F. Polymorphisms of the tumour necrosis factor α gene at position -308 and TNFd microsatellite in primary IgA nephropathy. Nephrol Dial Transplant 2003; 18:724-731.
59. Masutani K, Miyake K, Nakashima H, et al. Impact of interferon-γ and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients. Am J Kidney Dis 2003; 41:371-379.
60. Yoon H-J, Shin JH, Yang SH, et al. Association of the CD14 gene - 159C polymorphism with progression of IgA nephropathy. J Med Genet 2003; 40:104-108.
61. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26:354-357.
62. Kurogi Y. Mesangial cell proliferation inhibitors for the treatment of proliferate glomerular disease. Med Res Rev 2003; 23:15-31. This comprehensive review summarizes the mechanisms of many inhibitors of MC proliferation and the rationale for their potential as therapeutic agents for patients with IgA nephropathy.
63. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 2003; 18:241-245. This editorial reviews recent experience with immunosuppressive regimens for the treatment of patients with IgA nephropathy.
64. Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578-1583. This randomized prospective study found over a 6-year follow-up that ACE inhibitors significantly improved renal survival (defined as the absence of a 50% increase in serum creatinine) in patients with IgA nephropathy with 0.5 g/day or greater proteinuria and normal or moderately reduced renal function.
65. Park HC, Xu ZG, Choi S, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003; 18:1115-1121. In this randomized prospective treatment trial, losartan, but not amlodipine, decreased urinary excretion of protein and transforming growth factor β1, without a difference in blood pressure control. This study strengthens the rationale for the use of angiotensin II type 1 receptor antagonists in the treatment of patients with IgA nephropathy.
66. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63:1094-1103. This prospective, randomized, cross-over study of 24 patients with non-diabetic, chronic nephropathies (11 of whom had IgA nephropathy) showed that, with a comparable control of blood pressure, the combination of half-dose ACE inhibitor benazepril (10 mg/day) and angiotensin II type 1 receptor blocker valsartan (160 mg/day) decreased proteinuria better than either agent alone at the full dose.
67. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124. This prospective randomized study of 263 patients with non-diabetic proteinuric nephropathies (of whom 131 had IgA nephropathy) showed that treatment with an ACE inhibitor and angiotensin II type 1 receptor blocker in combination at half doses improved renal survival compared with full-dose monotherapy, at a comparable reduction of blood pressure. Improved renal survival was strongly associated with a greater reduction in proteinuria.
68. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91:457-465.
69. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
70. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18:1984-1992.
71. Kobayashi Y, Hiki Y, Kokubo T, et al. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996; 72:237-242.
72. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy. a randomised controlled trial. Lancet 1999; 353:883-887.
73. Waldo FB, Wyatt RJ, Kelly DR, et al. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 1993; 7:529-532.
74. Kuriki M, Asahi K, Asano K, et al. Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy. Nephrol Dial Transplant 2003; 18:1311-1315. Bolus intravenous glucocorticoid therapy followed by a tapering oral schedule over 12 months markedly lowered proteinuria and decreased the amount of mesangial matrix on repeat renal bbpsy in 16 IgA nephropathy patients with pretreatment glomerulosclerosis or adhesions in at least 10% of glomeruli.
75. Donadio JV Jr, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331:1194-1199.
76. Bene MC, Hurault De Ligny B, Kessler M, et al. Confirmation of tonsillar anomalies in IgA nephropathy: a multicenter study. Nephron 1991; 58:425-428.
77. Bene MC, de Ligny BH, Kessler M, et al. Tonsils in IgA nephropathy. Contrib Nephrol 1993; 104:153-161
78. Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63:1861-1867.
79. Nicholls K, Walker RG, Dowling JP, et al. 'Malignant' IgA nephropathy. Am J Kidney Dis 1985; 5:42-46.
80. Welch TR, McAdams AJ, Berry A. Rapidly progressive IgA nephropathy. Am J Dis Child 1988; 142:789-793.
81. Subias R, Botey A, Darnell A, et al. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol 1987; 27:1-7.
82. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18:1321-1329. This prospective open-labeled trial of 12 patients with crescentic IgA nephropathy showed that treatment with monthly intravenous cyclophosphamide and bolus methylprednisolone followed by oral prednisone stabilized serum creatinine concentration, reduced proteinuria, and reversed endocapillary proliferation and glomerular crescents after 6 months.
83. Berger J. Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 1988; 12:371-372.
84. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
85. Jeong HJ, Kim YS, Kwon KW, et al. Segmental glomerulosclerosis in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril. Clin Transplant 2003; 17:108-113.